Neutralising Antibody Molecules having Specificity for Human IL-17
AssigneeUCB Pharma S.A.
InventorsRalph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
Life of this patent
Estimating the term…
Abstract
The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
Claims19
(canceled)
A method of treating an IL-17 mediated pathological condition in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a neutralising antibody having specificity for human IL-17, wherein a variable domain of a heavy chain comprises at least one CDR having a sequence selected from SEQ ID NO:5 for CDR-H1, SEQ ID NO:6 for CDR-H2, and SEQ ID NO:7 for CDR-H3 and wherein a light chain comprises SEQ ID NO:13.
A method of treating an IL-17 mediated pathological condition in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a neutralising antibody having specificity for human IL-17, wherein the neutralising antibody binds to a same epitope as an antibody in which a variable domain of a heavy chain comprises sequence gH11 (SEQ ID NO:11) and a variable domain of a light chain comprises sequence gL3 (SEQ ID NO:
- 13).
Dependencies are inferred from the claim text.